A discovery about the mutated protein DECTIN-1, that limits the production of T regulatory cells, could lead to more effective drugs.
List view / Grid view
type 1 diabetes
The partial remission phase of type 1 diabetes, in which residual β-cells recover insulin production, offers new hope for therapeutic action.
Study led by UW Medicine reveals concerns about insulin pump therapy for type 1 diabetes patients. Long-term pump usage can lead to fibrotic, irritated infusion sites, making insulin delivery less effective
The new study highlights 11 genes which could be considered as potential candidates for novel therapeutics for type 1 diabetes.
Scientists have developed a novel type 1 diabetes treatment that involves transplanting pancreas cells that produce insulin.
In a new study, researchers from Osaka University have highlighted that mesenchymal stem cells could repress type 1 diabetes caused by cancer drugs.
A new study has identified harmful cellular pathways that prevent insulin production, presenting a drug target for diabetes.
Researchers have developed rapamycin-loaded nanocarriers capable of targeting cells related to pancreatic islet transplants without suppressing wider immune responses.
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
A study has shown that inhibiting the REST gene boosted insulin-producing cells during early pancreas development in animals.
JDRF funds development of an insulin-producing implant to regulate blood glucose levels in type 1 diabetes patients.
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.
Scientists have developed an implant that releases insulin-secreting cells which has shown success at treating diabetes in mice.
Combining two genomic methodologies, researchers have shown that pancreatic exocrine cells are implicated in type 1 diabetes.